You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Collins S, Joshi A, Shen L, et al
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0357